Ensitrelvir
Based on 16 publication(s) in Google Scholar
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).
For research use only. We do not sell to patients.
- Purity: 99.61%
- CAS No.: 2647530-73-0
- Formula: C22H17ClF3N9O2
- Molecular Weight:531.88
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Ensitrelvir
More- Nat Commun. 2023 Feb 25;14(1):1076. [Abstract]
- Emerg Microbes Infect. 2025 Dec;14(1):2552716. [Abstract]
- Anal Chem. 2026 Jun 23. [Abstract]
- ACS Omega. 2026 Jan 14;11(3):4541-4550. [Abstract]
- Structure. 2023 Sep 7;31(9):1016-1024.e3. [Abstract]
- J Biol Chem. 2023 Jul;299(7):104886. [Abstract]
- PNAS Nexus. 2025 Jan 7;4(1):pgae578. [Abstract]
- ACS Pharmacol Transl Sci. 2026 Jan 28.
- ACS Pharmacol Transl Sci. 2025 Oct 9;8(11):3944-3952. [Abstract]
- Res Sq. 2025 Jul 29.
- bioRxiv. 2025 May 30:2025.05.28.656516. [Abstract]
- Res Sq. 2025 Apr 20.
- bioRxiv. 2024 Feb 3.
- bioRxiv. 2023 Nov 27.
- bioRxiv. 2023 Oct 21.
- bioRxiv. 2023 Feb 27:2023.02.25.530000. [Abstract]
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero C1008 | CC50 |
>100 μM
Compound: S-216722
|
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 26 hrs by celltiter 96 aqueous non-radioactive cell proliferation assay
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 26 hrs by celltiter 96 aqueous non-radioactive cell proliferation assay
|
[PMID: 36107752] |
| Vero C1008 | EC50 |
0.35 μM
Compound: S-217622
|
Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells expressing TMPRSS2 assessed as reduction in virus-induced cytopathic effect measured after 48 hrs by cellular ATP assay
Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells expressing TMPRSS2 assessed as reduction in virus-induced cytopathic effect measured after 48 hrs by cellular ATP assay
|
[PMID: 37229831] |
In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants. EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2647530-73-0
-
Appearance Solid
-
Molecular Weight 531.88
-
Formula C22H17ClF3N9O2
-
Color White to light yellow
-
SMILES
FC1=C(CN2C(N(CC3=NN(C)C=N3)C(N/C2=N\C4=CC5=CN(C)N=C5C=C4Cl)=O)=O)C=C(F)C(F)=C1
-
Synonyms
S-217622
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. [Abstract]2023 Feb 25;14(1):1076. PMID: 36841831 -
Emerg Microbes Infect
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots. [Abstract]2025 Dec;14(1):2552716. PMID: 41088534 -
Anal Chem
Decoding Enzyme-Inhibitor Kinetic Mechanisms by Isothermal Titration Calorimetry: The Case of SARS-CoV-2 3CLpro. [Abstract]2026 Jun 23. PMID: 42334227 -
ACS Omega
Impact of Single Halogen Atom Substitutions on Antiviral Profile of Inhibitors Targeting SARS-CoV‑2 Main Protease. [Abstract]2026 Jan 14;11(3):4541-4550. PMID: 41626465 -
Structure
2023 Sep 7;31(9):1016-1024.e3. PMID: 37421945 -
J Biol Chem
Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors. [Abstract]2023 Jul;299(7):104886. PMID: 37271339 -
PNAS Nexus
An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. [Abstract]2025 Jan 7;4(1):pgae578. PMID: 39831159 -
-
ACS Pharmacol Transl Sci
Development of a Cell-Based Recombinant Green Fluorescent Protein Assay System for Generalized Discovery of Viral Protease Inhibitors. [Abstract]2025 Oct 9;8(11):3944-3952. PMID: 41262580 -
-
bioRxiv
A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity. [Abstract]2025 May 30:2025.05.28.656516. PMID: 40502047 -
-
-
-
-
bioRxiv
2023 Feb 27:2023.02.25.530000. PMID: 36909573
Solvent & Solubility
DMSO : 50 mg/mL (94.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8801 mL | 9.4006 mL | 18.8012 mL | 47.0031 mL |
| 5 mM | 0.3760 mL | 1.8801 mL | 3.7602 mL | 9.4006 mL | |
| 10 mM | 0.1880 mL | 0.9401 mL | 1.8801 mL | 4.7003 mL | |
| 15 mM | 0.1253 mL | 0.6267 mL | 1.2534 mL | 3.1335 mL | |
| 20 mM | 0.0940 mL | 0.4700 mL | 0.9401 mL | 2.3502 mL | |
| 25 mM | 0.0752 mL | 0.3760 mL | 0.7520 mL | 1.8801 mL | |
| 30 mM | 0.0627 mL | 0.3134 mL | 0.6267 mL | 1.5668 mL | |
| 40 mM | 0.0470 mL | 0.2350 mL | 0.4700 mL | 1.1751 mL | |
| 50 mM | 0.0376 mL | 0.1880 mL | 0.3760 mL | 0.9401 mL | |
| 60 mM | 0.0313 mL | 0.1567 mL | 0.3134 mL | 0.7834 mL | |
| 80 mM | 0.0235 mL | 0.1175 mL | 0.2350 mL | 0.5875 mL |